Accelerated Assessment
This article was originally published in SRA
Executive Summary
EMEA explains new accelerated assessment procedure
You may also be interested in...
EU Regulator Raises Possibility Of Shorter Drug Approval Timelines
With the EU pharmaceutical legislation due to undergo a radical shake-up to create a future-proof regulatory system, the time is ripe for industry to engage with efforts to make the European drug approval process more agile.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.